Cargando…

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma

BACKGROUND: Cyclin-dependent protein kinase 9 (CDK9) has been shown to play an important role in the pathogenesis of malignant tumors. However, the expression and function of CDK9 remain unknown in osteosarcomas. The purpose of this study is to assess the expression, function and clinical prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hangzhan, Seebacher, Nicole A., Hornicek, Francis J., Duan, Zhenfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355967/ https://www.ncbi.nlm.nih.gov/pubmed/30579871 http://dx.doi.org/10.1016/j.ebiom.2018.12.022

Ejemplares similares

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma
por: Li, Xiaoyang, et al.
Publicado: (2018)

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
por: Zhou, Yubing, et al.
Publicado: (2016)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2017)

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2018)

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
por: Kryštof, Vladimír, et al.
Publicado: (2012)

T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2021)

Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2021)

Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
por: Feng, Wenlong, et al.
Publicado: (2020)

Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Correction to: Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

MicroRNA Involvement in Osteosarcoma
por: Kobayashi, Eisuke, et al.
Publicado: (2012)

SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
por: Guo, Tao, et al.
Publicado: (2022)

Identification and Functional Characterisation of CRK12:CYC9, a Novel Cyclin-Dependent Kinase (CDK)-Cyclin Complex in Trypanosoma brucei
por: Monnerat, Séverine, et al.
Publicado: (2013)

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
por: Liao, Yunfei, et al.
Publicado: (2017)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study
por: Wei, Ran, et al.
Publicado: (2020)

T‐LAK cell‐originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2020)

MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma
por: Tang, Wei, et al.
Publicado: (2018)

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia
por: Yeh, Yuh-Ying, et al.
Publicado: (2014)

The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial
por: Nomura, Takashi, et al.
Publicado: (2019)

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway
por: Ni, Weiyu, et al.
Publicado: (2020)

Regulation of microRNAs function by circular RNAs in human cancer
por: Han, Chao, et al.
Publicado: (2017)

The Cyclin-dependent Kinase Cdk2 Regulates Thymocyte Apoptosis
por: Hakem, Anne, et al.
Publicado: (1999)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
por: Łukasik, Paweł, et al.
Publicado: (2021)

The role of extracelluar matrix in osteosarcoma progression and metastasis
por: Cui, Juncheng, et al.
Publicado: (2020)

Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae
por: Matrone, Gianfranco, et al.
Publicado: (2016)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
por: Liu, Tang, et al.
Publicado: (2016)

Cyclin-dependent kinase 5 (CDK5) regulates the circadian clock
por: Brenna, Andrea, et al.
Publicado: (2019)

Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth
por: Zhou, Yubing, et al.
Publicado: (2015)

Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
por: Sun, Ranran, et al.
Publicado: (2016)

Cyclin-Dependent Kinase 9 Activity Regulates Neutrophil Spontaneous Apoptosis
por: Wang, Keqing, et al.
Publicado: (2012)

Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma
por: Tong, Zhimin, et al.
Publicado: (2017)

Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
por: Alsfouk, Aisha
Publicado: (2021)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

Expression and Clinical Significance of High‐Mobility Group AT‐hook 2 (HMGA2) in Osteosarcoma
por: Cui, Juncheng, et al.
Publicado: (2022)

Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients
por: van Nes, J G H, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7oeogckvrldv7sq4hlu0mr5q8k